Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators. Delmas PD, et al. Among authors: eastell r. J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17. doi: 10.1210/jcem.87.8.8750. J Clin Endocrinol Metab. 2002. PMID: 12161484 Clinical Trial.
Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.
Compston JE, Audran M, Avouac B, Bouvenot G, Devogelaer J, Eastell R, Fabris F, Gennari C, Jones EA, Kaufman JM, Lemmel E, Mazzuoli G, Reid DM, Ringe JD, Vanhaelst L, Ziegler R, Reginster JY. Compston JE, et al. Among authors: eastell r. Calcif Tissue Int. 1996 Nov;59(5):323-7. doi: 10.1007/s002239900134. Calcif Tissue Int. 1996. PMID: 8849396 No abstract available.
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Reginster J, et al. Among authors: eastell r. Osteoporos Int. 2000;11(1):83-91. doi: 10.1007/s001980050010. Osteoporos Int. 2000. PMID: 10663363 Clinical Trial.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. McClung MR, et al. Among authors: eastell r. N Engl J Med. 2001 Feb 1;344(5):333-40. doi: 10.1056/NEJM200102013440503. N Engl J Med. 2001. PMID: 11172164 Free article. Clinical Trial.
638 results